Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.64 |
| ▸ | MAOB | P27338 | 5/20 | 0.61 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | RXRB | P28702 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991977 | 0.92 | PPARA (0.73) | PPARAMAOBPPARGPPARD | |
| SCHEMBL21991948 | 0.88 | PPARA (0.68) | PPARAMAOBPPARGPPARD | |
| SCHEMBL21991358 | 0.87 | MAOB (0.59) | PPARAMAOBPPARGFFAR1NR4A2 | |
| SCHEMBL21991326 | 0.86 | MAOB (0.64) | PPARAMAOBPPARGPPARDFFAR1 | |
| SCHEMBL21991982 | 0.85 | MAOB (0.56) | PPARAMAOBPPARGFFAR1NR4A2 | |
| SCHEMBL21991603 | 0.84 | MAOB (0.55) | PPARAMAOBPPARGFFAR1NR4A2 | |
| SCHEMBL21991607 | 0.84 | PPARA (0.62) | PPARAMAOBPPARGPPARDFFAR1 | |
| SCHEMBL13279808 | 0.83 | MAOB (0.68) | PPARAMAOBPPARGPPARDFFAR1 | |
| SCHEMBL21991794 | 0.81 | PPARA (0.77) | PPARAMAOBPPARGPPARDFFAR1 | |
| SCHEMBL21991284 | 0.81 | MAOB (0.63) | PPARAMAOBPPARGPPARDFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885MAOB 3946/4885PPARG 1583/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | PPARA 806/4885MAOB 3946/4885PPARG 1583/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885MAOB 3946/4885PPARG 1583/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885MAOB 3946/4885PPARG 1583/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885MAOB 3946/4885PPARG 1583/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885MAOB 3946/4885PPARG 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.